TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03265886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warm bupivacaine at (37°c)
Description: Bupivacaine 0.5%, 30 mL, warmed to 37◦C for 20 minutes. The empty syringes and needles, in their packaging, will be held at the same temperature before initiating the block.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine at operating room temperature (23°c)
Description: Bupivacaine 0.5%, 30 ml held in crash shelf of the operating room temperature at 23◦C. The empty syringes and needles will be held in the same temperature before use.
Study: NCT03639519

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Carbonated orange beverage
Description: The carbonated orange beverage will be administered at the night before surgery and will be continued for five days
Study: NCT03144102

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Virtual Reality-based therapy for upper-limbs motor rehabilitation
Description: During each session, the subject will perform 4 VR-based exercises that involve reaching, grasping, and intercepting virtual objects. The training will last a total of 30 min per session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality-based therapy for upper-limbs motor rehabilitation
Description: During each session, the subject will perform 4 VR-based exercises that involve reaching, grasping, and intercepting virtual objects. The training will last a total of 30 min per session.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Anodal transcranial direct-current stimulation (tDCS)
Description: Concurrent anodal tDCS on sensorimotor cortex on the ipsilesional hemisphere.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct-current stimulation (tDCS)
Description: Concurrent anodal tDCS on sensorimotor cortex on the ipsilesional hemisphere.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Occupational Therapy for upper-limbs motor rehabilitation
Description: During each session, the subject will perform 4 occupational therapy exercises that involve reaching, grasping, and intercepting objects. The training will last a total of 30 min per session.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Occupational Therapy for upper-limbs motor rehabilitation
Description: During each session, the subject will perform 4 occupational therapy exercises that involve reaching, grasping, and intercepting objects. The training will last a total of 30 min per session.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham transcranial direct-current stimulation (tDCS)
Description: Concurrent sham tDCS on sensorimotor cortex on the ipsilesional hemisphere.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham transcranial direct-current stimulation (tDCS)
Description: Concurrent sham tDCS on sensorimotor cortex on the ipsilesional hemisphere.
Study: NCT01366378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylnaltrexone
Study: NCT03331237

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: scalene block
Description: scalene block using 5ml of ropivacaine

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ISO block
Description: ISO block is a combined block of suprascapular nerve and brachial plexus cords using a single puncture
Study: NCT01322126

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasound probe
Description: we will compare two technique of neuraxial anesthesia;one group will be passed neuraxial anesthesia with the intervention the ultrasound and the other group without the intervention of the ultrasound.
Study: NCT02059720

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: HSCT
Description: Patients randomly assigned in to either of groups will receive either autologous SCT or haplo-SCT after CR1 is achieved.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: HSCT
Description: Patients randomly assigned in to either of groups will receive either autologous SCT or haplo-SCT after CR1 is achieved.
Study: NCT01274806

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: Core Stability Exercise, Endurance training, recovery massage
Study: NCT01369017

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anakinra
Description: Active treatment will consist of 2 doses of 1 mg/kg up to 100 mg of anakinra SQ injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injection of NS
Study: NCT04235699

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional and Dietary Manipulation
Description: Participants will undertake a controlled feeding intervention. All food will be prepared and delivered to participants by research staff. Participants will be asked to exclusively eat what is provided to them in efforts to control any dietary effects.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional and Dietary Manipulation
Description: Participants will undertake a controlled feeding intervention. All food will be prepared and delivered to participants by research staff. Participants will be asked to exclusively eat what is provided to them in efforts to control any dietary effects.
Study: NCT03832699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dydrogesterone 10 MG
Description: Oral progesterone 10 mg TID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Endometrin 100Mg Vaginal Insert
Description: Vaginal Endometrin 100 mg twice daily
Study: NCT00995085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended Release Metadoxine
Description: one oral 1400mg dose (2 tablets)
Study: NCT01314378

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Training
Description: Eight session intensive behavioral training program for smokers

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-Behavioral Therapy
Description: Eight session intensive behavioral intervention for smokers
Study: NCT02516904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD101 IV
Description: antifungal

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: normal saline
Study: NCT03175289

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Undergo therapy session conducted by a speech pathologist

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice
Description: Undergo therapy session conducted by a speech pathologist

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Intervention
Description: Receive standard of care patient education materials focusing on oral care, signs/symptoms of dysphagia/aspiration, and trismus

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Receive standard of care patient education materials focusing on oral care, signs/symptoms of dysphagia/aspiration, and trismus

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Intervention
Description: Perform prescribed home exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Perform prescribed home exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Expiratory Muscle Strength Training
Description: Participate in EMST

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05283863

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham Stimulation
Description: Patients in this group will receive receive sham spinal cord stimulation (aka no stimulation) for 2 weeks.
Study: NCT01917448

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: spinal morphine 0.15 mg

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: control
Description: Patient receive only local infiltration without spinal analgesia
Study: NCT01441388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib plus axitinib
Description: Study drugs are tablets or capsules; dosage, frequency and duration to be determined.
Study: NCT05283863

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Stimulation
Description: Patients in this group will receive receive sham spinal cord stimulation (aka no stimulation) for 2 weeks.
Study: NCT01441388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib plus sunitinib
Description: Study drugs are tablets or capsules; dosage, frequency and duration to be determined.
Study: NCT02365779

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bilateral laparoscopic salpingectomy
Description: Use of the confocal laser endomicroscopy Cellvizio® system during laparoscopy salpingectomy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: endomicroscopy Cellvizio® system
Study: NCT01441388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib plus axitinib
Description: Study drugs are tablets or capsules; dosage, frequency and duration to be determined.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib plus sunitinib
Description: Study drugs are tablets or capsules; dosage, frequency and duration to be determined.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib plus bevacizumab
Description: Study drugs are tablets or capsules except for bevacizumab which is parenteral (intravenous). Dosage, frequency and duration to be determined.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib plus sorafenib
Description: Study drugs are tablets or capsules; dosage, frequency and duration to be determined.
Study: NCT02319486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin periocular injection
Description: chemotherapy together with/without 20mg/2ml carboplatin periocular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CEV chemotherapy
Description: vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2
Study: NCT03508518

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shared care device in psychiatry (DSPP)
Description: The GPs of the intervention group will be able to refer their patients to the DSPP or to the routine care. The patient has a nursing telephone interview prior to one or few more psychiatric consultations. The time to obtain the psychiatric consultation is measured into the 2 groups. In both groups, questionnaires will be sent to the patient and their medico-administrative data will be collected passively over a period of 6 months after inclusion
Study: NCT01883024

Intervention type: OTHER
Group type: OTHER
Intervention: A decision support software

Intervention type: OTHER
Group type: OTHER
Intervention: Insulin Pump

Intervention type: OTHER
Group type: OTHER
Intervention: Continuous glucose monitoring
Study: NCT00099021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pioglitazone hydrochloride
Description: Given PO
Study: NCT01409330

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: diet intervention
Description: 8-week diet lacking red meat, but containing increased fibers and coffee (verum) versus standard recommendation (control) eating red meat.
Study: NCT01077570

Intervention type: DRUG
Intervention: repaglinide
Description: Repaglinide prescribed at the discretion of the investigator, according to local labelling, and evaluated at week 0, 8 and 16 of the study
Study: NCT04447651

Intervention type: OTHER
Intervention: Recommendation for treatment with immunotherapy
Description: Patients with a SF3B1, U2AF1 or SRSF2 mutation will be reviewed by the molecular tumor board and treatment recommendations will be given to the patient's treating oncologist.
Study: NCT02098967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6839921
Description: Non-escalating IV doses given on Days 1-5 of Cycle 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6839921
Description: Escalating IV doses of RO6839921 in solid tumor patients. Dose escalation will be calculated using the new Continual Reassessment Method (nCRM). RO6839921 will be given on Days 1-5 of 28-day cycles. Treatment will continue until disease progression, unacceptable toxicity or study discontinuation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6839921
Description: Escalating IV doses of RO6839921 in AML patients. Escalation will follow an adapted rolling 6 design. Starting dose \</= dose inducing Grade 2 toxicity in patients with solid tumors. RO6839921 will be given on Days 1-5 of 28-day cycles. Treatment will continue until disease progression, unacceptable toxicity or study discontinuation.
Study: NCT03441308

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Educational method of group treatment

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational method of group treatment
Study: NCT02807363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Oral Tablet 4-mg QD
Description: 4-mg Leuprolide oral tablet once daily for 28 consecutive days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Oral Tablet 4-mg BID
Description: 4-mg Leuprolide oral tablet twice daily for 28 consecutive days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprolide Depot
Description: 3.75 mg intramuscular depot injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Oral Tablet 10-mg BID
Description: 10-mg Leuprolide oral tablet twice daily for 28 consecutive days.
Study: NCT02674672

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VenaTech® (VenaTech Retrievable Filter)
Study: NCT01623141

Intervention type: PROCEDURE
Intervention: Pressure Pain measurement
Description: The pressure pain thresholds were established using a manual pressure algometer. The investigated joints were the carpus, the metacarpophalangeal and the proximal interphalangeal joints

Intervention type: PROCEDURE
Intervention: Pressure Pain measurement
Description: The pressure pain thresholds were established using a manual pressure algometer. The investigated joints were the carpus, the metacarpophalangeal and the proximal interphalangeal joints

Intervention type: PROCEDURE
Intervention: Pressure Pain measurement
Description: The pressure pain thresholds were established using a manual pressure algometer. The investigated joints were the carpus, the metacarpophalangeal and the proximal interphalangeal joints
Study: NCT00084812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: safingol
Study: NCT01142284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol, Probucol
Description: Treatment Group 1 (control) No cilostazol or probucol~Treatment Group 2 (cilostazol alone) 1 tablet cilostazol 100 mg PO BID~Treatment Group 3 (probucol alone) 1 tablet probucol 250 mg PO BID~Treatment Group 4 (concomitant cilostazol and probucol) 1 tablet cilostazol 100 mg PO BID, and 1 tablet probucol 250 mg PO BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol, Probucol
Description: Treatment Group 1 (control) No cilostazol or probucol~Treatment Group 2 (cilostazol alone) 1 tablet cilostazol 100 mg PO BID~Treatment Group 3 (probucol alone) 1 tablet probucol 250 mg PO BID~Treatment Group 4 (concomitant cilostazol and probucol) 1 tablet cilostazol 100 mg PO BID, and 1 tablet probucol 250 mg PO BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cilostazol, Probucol
Description: Treatment Group 1 (control) No cilostazol or probucol~Treatment Group 2 (cilostazol alone) 1 tablet cilostazol 100 mg PO BID~Treatment Group 3 (probucol alone) 1 tablet probucol 250 mg PO BID~Treatment Group 4 (concomitant cilostazol and probucol) 1 tablet cilostazol 100 mg PO BID, and 1 tablet probucol 250 mg PO BID
Study: NCT03508518

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: psychiatric care available in the Haute Garonne: psychiatric consultation by a liberal psychiatrist or by a psychiatrist working in public health center.
Study: NCT01065259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OROS MPH
Description: The dosage began with 18mg Qd. It can be increased with 18mg every week until an optimal response achieved. The maximum dosage was no more than 54mg/d. The optimal dosage will maintain for 4 to 6 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atomoxetine
Description: The dosage begins with 0.5mg/kg.d. It can increased to 0.8mg/kg.d at the second week, 1.2mg/kg.d at the third week, and 1.4mg/kg.d at the 5th week according to the patients response. The optimal dosage will maintain for 4 to 6 weeks.
Study: NCT05223244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupivacaine, triamcinolone, and heparin (BTH)
Description: 30mL of 0.5% bupivacaine (5mg/mL), 2mL triamcinolone (10mg/mL), and 2mL Heparin (10,000units/mL)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dimethyl sulfoxide (DMSO)
Description: 50mL of DMSO and 1mL of triamcinolone (10mg/mL)
Study: NCT02126917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HC-ER + 40% Alcohol
Description: HC-ER 50 mg + 240 mL solution of 40% alcohol/orange juice in fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HC-ER + 20% Alcohol
Description: HC-ER 50 mg + 240 mL solution of 20% alcohol/orange juice in fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HC-ER + 0% Alcohol
Description: HC-ER 50 mg + 240 mL solution of 0% alcohol/orange juice in fasted state
Study: NCT02655588

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive Media-Based Problems Solving Treatment
Study: NCT05447975

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tai Chi training
Description: As for Tai Chi training, standardized Tai Chi was taught by professional Tai Chi coaches from Sino Taiji of Fuxing International in classes: Qishi (Starting Posture), Shangsanbu (Twist Step), Yema Fenzong(Part the Wild Horse's Mane on Both Side), Jingang Daozhui (Buddha's warrior attendant pounds mortar), Shoushi (Closing Posture). Patients participated in this class were trained, twice a week, 60 min per time. PD patients whose attendance rate less than 75% were excluded.
Study: NCT00637936

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen
Description: Inspiratory fraction during anaesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen
Description: Inspiratory fraction during anaesthesia
Study: NCT01295697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EZN-2208
Description: Experimental
Study: NCT02748317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG
Description: For the intravesicular Lactobacillus instillation, participants will be instructed to mix the contents of 1 Lactobacillus capsule into 45 cc sterile 0.9% saline.5,6 After mixing, participants will draw up the 45 cc of the liquid Lactobacillus mixture into a 60cc catheter tip syringe and instill via the intermittent catheter after the last catheterization prior to going to bed. Participants will receive 10 Lactobacillus GG tabs at the beginning of treatment phase. At the end of each month, the coordinator or RA will ask how many remaining tablets the participant has, and if needed dispense the next supply of 10 tablets Participants will be instructed to complete the USQ-NB weekly.
Study: NCT01142284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol, Probucol
Description: Treatment Group 1 (control) No cilostazol or probucol~Treatment Group 2 (cilostazol alone) 1 tablet cilostazol 100 mg PO BID~Treatment Group 3 (probucol alone) 1 tablet probucol 250 mg PO BID~Treatment Group 4 (concomitant cilostazol and probucol) 1 tablet cilostazol 100 mg PO BID, and 1 tablet probucol 250 mg PO BID
Study: NCT00676936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Custom made capsules, Methylprednisolone 16 mg twice daily, intervention period 7 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Custom made capsules, Lactose, administered twice daily, intervention period 7 days
Study: NCT02335112

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Irreversible electroporation (IRE)
Description: Irreversible Electroportion For Unresectable Head and Neck Neoplasms guide with ultrasound or/and CT.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Irreversible electroporation (IRE)
Description: Irreversible Electroportion For Unresectable Head and Neck Neoplasms guide with ultrasound or/and CT.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Irreversible electroporation (IRE)
Description: Irreversible Electroportion For Unresectable Head and Neck Neoplasms guide with ultrasound or/and CT.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NanoKnife

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NanoKnife

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NanoKnife
Study: NCT04643223

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: kinesio tape with tension
Description: The application of kinesio tape follows a protocol, which involves the sanitization of the selected scar with liquid soap, drying and application of alcohol to remove sebum. Measurement of the scar and marking of the therapeutic zone and anchors. Following the application of kinesio tape, with tension between seventy to ninety percent on the treated hypertrophic scar. This process follows the routine of patient care established by the service and will continue for a period corresponding to three months. In which, the evaluations of Vancouver, the collections of cicatricial material will be carried out, in the time spaces corresponding to forty-five and ninety days, having as reference the initial evaluation made after being elected.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: kinesio tape without tension
Description: The application of kinesio tape without tension follows a protocol, which involves the sanitization of the selected scar with liquid soap, drying and application of alcohol to remove sebum. Measurement of the scar and marking of the therapeutic zone and anchors. Following application of the kinesio tape, no tension on the treated hypertrophic scar. This process follows the routine of patient care established by the service and will continue for a period corresponding to three months. In which, the evaluations of Vancouver, the collections of cicatricial material will be carried out, in the time spaces corresponding to forty-five and ninety days, having as reference the initial evaluation made after being elected.
Study: NCT01551134

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fundoplication
Description: Primary fundoplication

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fundoplication
Description: Primary fundoplication